SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2024 Jan 8:S2152-2650(23)02202-4. doi: 10.1016/j.clml.2023.12.013. Online ahead of print.ABSTRACTThe integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%. In older patients, using less intensive chemotherapy (mini-H...
Source: Clinical Lymphoma and Myeloma - January 9, 2024 Category: Cancer & Oncology Authors: Jayastu Senapati Hagop Kantarjian Fadi G Haddad Nicholas J Short Mary Alma Welch Nitin Jain Elias Jabbour Source Type: research
Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study
CONCLUSIONS: Despite increases in autoHCT utilization, sociodemographic disparities remain. Identifying and mitigating barriers to autoHCT is essential to ensuring more equitable access to this highly effective therapy.PMID:38195324 | DOI:10.1016/j.clml.2023.12.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 9, 2024 Category: Cancer & Oncology Authors: Naseem S Esteghamat Ann Brunson Aaron S Rosenberg Sara J Schonfeld Bryan Valcarcel Renata Abrah ão Julianne J P Cooley Christa L Meyer Jeffery J Auletta Lindsay M Morton Lori Muffly Ted Wun Theresa H M Keegan Source Type: research
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 29:S2152-2650(23)02200-0. doi: 10.1016/j.clml.2023.12.011. Online ahead of print.ABSTRACTLong-term survival outcomes of patients with chronic myeloid leukemia in the chronic phase are now similar to those of the general population, following the introduction of ABL1 tyrosine kinase inhibitors (TKIs). Approximately 40% to 80% of patients with chronic myeloid leukemia successfully achieved treatment-free remission after the first attempt of TKI discontinuation (TFR1), after achieving a durable deep molecular response. However, the possibility of achieving treatment-free remission after a ...
Source: Clinical Lymphoma and Myeloma - January 9, 2024 Category: Cancer & Oncology Authors: Hiroshi Ureshino Kazuharu Kamachi Shinya Kimura Source Type: research
Multiple Myeloma: Validation of the Values and Preferences Elicitation Questionnaire- Cure and Survival Preference Scale (VPEQ-CSPS)
This study examined the psychometric properties of the Values and Preferences Elicitation Questionnaire-Cure and Survival Preference Scale (VPEQ-CSPS) instrument.METHODS: The VPEQ-CSPS instrument was deployed using an anonymous Qualtrics online survey to patients diagnosed with MM within the network of International Myeloma Foundation online patient support groups across the United States. One hundred seventy-four (N = 174) valid responses were obtained and used to examine the validity and reliability of the VPEQ-CSPS.RESULTS: Exploratory factor analysis (EFA) revealed a Kaiser-Meyer-Olkin value of 0.72 indicating excellen...
Source: Clinical Lymphoma and Myeloma - January 7, 2024 Category: Cancer & Oncology Authors: Anastasiia Savchenko Joseph D Tariman Alexandria Kohon Shannon D Simonovich Thomas Dahan Jessica Bishop-Royse Source Type: research
SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 14:S2152-2650(23)02196-1. doi: 10.1016/j.clml.2023.12.007. Online ahead of print.ABSTRACTThe outcome of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has improved significantly following the introduction of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). The addition of newer-generation and more potent TKIs resulted in higher rates of molecular responses and better survival. Achieving a complete molecular remission (CMR; disappearance of the BCR::ABL1 transcripts) within the first 3 months of therapy is an important endpoint in newly diagnosed Ph-positive ALL...
Source: Clinical Lymphoma and Myeloma - January 7, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Elias Jabbour Nicholas J Short Nitin Jain Hagop Kantarjian Source Type: research
Multiple Myeloma: Validation of the Values and Preferences Elicitation Questionnaire- Cure and Survival Preference Scale (VPEQ-CSPS)
This study examined the psychometric properties of the Values and Preferences Elicitation Questionnaire-Cure and Survival Preference Scale (VPEQ-CSPS) instrument.METHODS: The VPEQ-CSPS instrument was deployed using an anonymous Qualtrics online survey to patients diagnosed with MM within the network of International Myeloma Foundation online patient support groups across the United States. One hundred seventy-four (N = 174) valid responses were obtained and used to examine the validity and reliability of the VPEQ-CSPS.RESULTS: Exploratory factor analysis (EFA) revealed a Kaiser-Meyer-Olkin value of 0.72 indicating excellen...
Source: Clinical Lymphoma and Myeloma - January 7, 2024 Category: Cancer & Oncology Authors: Anastasiia Savchenko Joseph D Tariman Alexandria Kohon Shannon D Simonovich Thomas Dahan Jessica Bishop-Royse Source Type: research
SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 14:S2152-2650(23)02196-1. doi: 10.1016/j.clml.2023.12.007. Online ahead of print.ABSTRACTThe outcome of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has improved significantly following the introduction of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). The addition of newer-generation and more potent TKIs resulted in higher rates of molecular responses and better survival. Achieving a complete molecular remission (CMR; disappearance of the BCR::ABL1 transcripts) within the first 3 months of therapy is an important endpoint in newly diagnosed Ph-positive ALL...
Source: Clinical Lymphoma and Myeloma - January 7, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Elias Jabbour Nicholas J Short Nitin Jain Hagop Kantarjian Source Type: research
Recent advances and future perspectives of T-cell engagers in lymphoid malignancies
Jpn J Clin Oncol. 2024 Jan 5:hyad186. doi: 10.1093/jjco/hyad186. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are monoclonal antibodies that simultaneously bind to a specific antigen on tumors and CD3 on T cells, leading to T cell activation and subsequent tumor cell lysis. Several CD20 × CD3 BsAbs are being developed for B-cell lymphomas. Furthermore, multiple clinical trials to evaluate BsAbs for the treatment of multiple myeloma, with targets including BCMA, GPRC5D and FcRH5, are ongoing. Emerging evidence suggests promising efficacy in heavily pretreated patients with relapsed or refractory lymphoid mal...
Source: Clinical Lymphoma and Myeloma - January 6, 2024 Category: Cancer & Oncology Authors: Yuko Shirouchi Dai Maruyama Source Type: research
Recent advances and future perspectives of T-cell engagers in lymphoid malignancies
Jpn J Clin Oncol. 2024 Jan 5:hyad186. doi: 10.1093/jjco/hyad186. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are monoclonal antibodies that simultaneously bind to a specific antigen on tumors and CD3 on T cells, leading to T cell activation and subsequent tumor cell lysis. Several CD20 × CD3 BsAbs are being developed for B-cell lymphomas. Furthermore, multiple clinical trials to evaluate BsAbs for the treatment of multiple myeloma, with targets including BCMA, GPRC5D and FcRH5, are ongoing. Emerging evidence suggests promising efficacy in heavily pretreated patients with relapsed or refractory lymphoid mal...
Source: Clinical Lymphoma and Myeloma - January 6, 2024 Category: Cancer & Oncology Authors: Yuko Shirouchi Dai Maruyama Source Type: research
Recent advances and future perspectives of T-cell engagers in lymphoid malignancies
Jpn J Clin Oncol. 2024 Jan 5:hyad186. doi: 10.1093/jjco/hyad186. Online ahead of print.ABSTRACTBispecific antibodies (BsAbs) are monoclonal antibodies that simultaneously bind to a specific antigen on tumors and CD3 on T cells, leading to T cell activation and subsequent tumor cell lysis. Several CD20 × CD3 BsAbs are being developed for B-cell lymphomas. Furthermore, multiple clinical trials to evaluate BsAbs for the treatment of multiple myeloma, with targets including BCMA, GPRC5D and FcRH5, are ongoing. Emerging evidence suggests promising efficacy in heavily pretreated patients with relapsed or refractory lymphoid mal...
Source: Clinical Lymphoma and Myeloma - January 6, 2024 Category: Cancer & Oncology Authors: Yuko Shirouchi Dai Maruyama Source Type: research
The Prognostic Significance of Vitamin D Deficiency in Korean Patients With Multiple Myeloma
CONCLUSION: These findings suggest that vitamin D levels are a significant prognostic factor in patients with multiple myeloma.PMID:38177055 | DOI:10.1016/j.clml.2023.12.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 4, 2024 Category: Cancer & Oncology Authors: Sejin Kim Hyungwoo Cho Miyoung Kim Kyoungmin Lee Shin Kim Dok Hyun Yoon Source Type: research
The Prognostic Significance of Vitamin D Deficiency in Korean Patients With Multiple Myeloma
CONCLUSION: These findings suggest that vitamin D levels are a significant prognostic factor in patients with multiple myeloma.PMID:38177055 | DOI:10.1016/j.clml.2023.12.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 4, 2024 Category: Cancer & Oncology Authors: Sejin Kim Hyungwoo Cho Miyoung Kim Kyoungmin Lee Shin Kim Dok Hyun Yoon Source Type: research
Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab
CONCLUSIONS: R/R LBCL patients reported consistent, clinically meaningful improvements in symptoms and HRQoL and satisfaction with epcoritamab.PMID:38151388 | DOI:10.1016/j.clml.2023.11.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Tycel Phillips Pieternella Lugtenburg Anupama Kalsekar Alex Mutebi Anthony Wang Julie Blaedel Katherine Kosa Susan Martin Mariana Sacchi Nurgul Kilavuz Catherine Thieblemont Source Type: research
SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra"
Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02189-4. doi: 10.1016/j.clml.2023.11.011. Online ahead of print.ABSTRACTChronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developin...
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Elisabetta Abruzzese Malgorzata Monika Trawinska Paolo De Fabritiis Simona Bernardi Source Type: research
The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
CONCLUSION: Our study shows that a TDT equal to or less than 1 week is associated with adverse clinical factors, worse outcomes, and response in DLBCL, even after adjusting for multiple known poor prognostic factors. This was the first time that response to first-line therapy was correlated to time to treatment. Our findings support ongoing efforts to improve currently standardized prognostic tools and the incorporation of TDT into clinical trials to avoid selection bias.PMID:38151390 | DOI:10.1016/j.clml.2023.11.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Gabriel Roman Souza Zohra Nooruddin Sophia Lee Lauren Boyle Kana Tai Lucero Snegha Ananth Kathleen Franklin Michael Mader Esteban Toro Velez Amna Naqvi Supreet Kaur Source Type: research